الفهرس 
Introduction
Glioblastoma multiforme overviewOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
”Glioblastoma multiforme is the most malignant and frequently occurring type of primary astrocytomas. It is responsible for 57 percent of all gliomas and 48 percent of all primary central nervous system tumors.Despite the variety of modern therapies against GBM, it is still a deadly disease with extremely poor prognosis. Treatment of newly diagnosed GBM requires a multidisciplinary approach. Current standard therapy includes maximal safe surgical resection, followed by concurrent radiation with temozolomide (TMZ) (Temodar®), an oral alkylating chemotherapy agent, and then adjuvant chemotherapy with TMZ .Better local control, mostly through the application of chemotherapy, as well as advances in surgical and radiation procedures, have resulted in increased survival rates.Several factors, Clinically (age, performance status), treatment (quality of surgery, radiation, chemotherapy), and tumour features (volume, site, primary or secondary) have all been researched to see how they affect outcomes. Young age, a good ECOG performance status at the initial diagnosis, radiation, and tumour resection degree have all been proposed as significant prognostic variables for GBM cases.Our study was a retrospective study which assed treatment outcome and prognostic factors of glioblastoma multiforme patients registered in our department in the period from January 2012 to december 2017 with evaluation treatment outcome and any asscociated prognostic factor affected the survival.